Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
293
Views
1
CrossRef citations to date
0
Altmetric
Review

Directing Dendritic Cell Immunotherapy Towards Successful Cancer Treatment

Rachel Lubong SabadoNew York University School of Medicine, NYU Langone Medical Center Cancer Institute, 550 First Avenue SML 1303, New York, NY10016, USA. Tel.: +1 212 263 5814 Fax: +1 212 263 [email protected]; [email protected]View further author information
&
Nina BhardwajNew York University School of Medicine, NYU Langone Medical Center Cancer Institute, 550 First Avenue SML 1303, New York, NY10016, USA. Tel.: +1 212 263 5814 Fax: +1 212 263 [email protected]; [email protected]View further author information
Pages 37-56 | Published online: 17 Dec 2009

Bibliography

  • Banchereau J , BriereF, CauxC et al.: Immunobiology of dendritic cells.Annu. Rev. Immunol.18 , 767–811 (2000).
  • Naik SH , SatheP, ParkHY et al.: Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo.Nat. Immunol.8(11) , 1217–1226 (2007).
  • Mckenna K , BeignonAS, BhardwajN: Plasmacytoid dendritic cells: linking innate and adaptive immunity.J. Virol.79(1) , 17–27 (2005).
  • Salio M , CellaM, VermiW et al.: Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.Eur. J, Immunol, 33(4) , 1052–1062 (2003).
  • Hartmann E , WollenbergB, RothenfusserS et al.: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.Cancer Res.63(19) , 6478–6487 (2003).
  • Dunn GP , BruceAT, SheehanKC et al.: A critical function for type I interferons in cancer immunoediting.Nat. Immunol.6(7) , 722–729 (2005).
  • Gerlini G , UrsoC, MariottiG et al.: Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.Clin. Immunol.125(2) , 184–193 (2007).
  • Battaglia A , BuzzonettiA, BaranelloC et al.: Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.Cancer Immunol. Immunother.58(9) , 1363–1373 (2009).
  • Sharma MD , BabanB, ChandlerP et al.: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature tregs via indoleamine 2,3-dioxygenase.J. Clin. Invest.117(9) , 2570–2582 (2007).
  • Munn D h, Sharma Md, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest.114(2) , 280–290 (2004).
  • Trinchieri G : Interleukin-12 and the regulation of innate resistance and adaptive immunity.Nat. Rev. Immunol.3(2) , 133–146 (2003).
  • Guermonprez P , ValladeauJ, ZitvogelL, TheryC, AmigorenaS: Antigen presentation and T-cell stimulation by dendritic cells.Annu. Rev. Immunol.20 , 621–667 (2002).
  • Mori L , De Libero G: Presentation of lipid antigens to T cells. Immunol. Lett.117(1) , 1–8 (2008).
  • Ishikawa A , MotohashiS, Ishikawa Eet al.: A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res.11(5) , 1910–1917 (2005).
  • Seino K , MotohashiS, FujisawaT, NakayamaT, TaniguchiM: Natural killer T cell-mediated anti-tumor immune responses and their clinical applications.Cancer Sci.97(9) , 807–812 (2006).
  • Cambi A , KoopmanM, FigdorCG: How C-type lectins detect pathogens.Cell. Microbiol7(4) , 481–488 (2005).
  • Van Vliet SJ , Garcia-VallejoJJ, Van Kooyk Y: Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol. Cell. Biol.86(7) , 580–587 (2008).
  • Tacken PJ , De Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10) , 790–802 (2007).
  • Tacken PJ , De Vries IJ, Gijzen K et al.: Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood106(4) , 1278–1285 (2005).
  • Bonifaz LC , BonnyayDP, CharalambousA et al.: in vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T-cell vaccination.J. Exp. Med.199(6) , 815–824 (2004).
  • Smith AL , GaneshL, LeungK,Jongstra-Bilen J, Jongstra J, Nabel GJ: Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J. Exp. Med.204(2) , 421–430 (2007).
  • Akira S , TakedaK: Toll-like receptor signalling.Nat. Rev. Immunol.4(7) , 499–511 (2004).
  • Kato H , TakeuchiO, SatoS et al.: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.Nature441(7089) , 101–105 (2006).
  • Pedra JH , CasselSL, SutterwalaFS: Sensing pathogens and danger signals by the inflammasome.Curr. Opin. Immunol.21(1) , 10–16 (2009).
  • Skoberne M , BeignonAS, BhardwajN: Danger signals: a time and space continuum.Trends Mol. Med.10(6) , 251–257 (2004).
  • Martin-Fontecha A , LanzavecchiaA, SallustoF: Dendritic cell migration to peripheral lymph nodes.Handb. Exp. Pharmacol. (188) , 31–49 (2009).
  • Scholer A , HuguesS, BoissonnasA, FetlerL, AmigorenaS: Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T-cell memory.Immunity28(2) , 258–270 (2008).
  • Peggs KS , QuezadaSA, AllisonJP: Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.Immunol. Rev.224 , 141–165 (2008).
  • Elgueta R , BensonMJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev.229(1) , 152–172 (2009).
  • Sallusto F , LanzavecchiaA: Human Th17 cells in infection and autoimmunity.Microbes Infect.11(5) , 620–624 (2009).
  • Tang Q , BluestoneJA: The 3+ regulatory T cell: a jack of all trades, master of regulation.Nat. Immunol.9(3) , 239–244 (2008).
  • Sokol CL , ChuNQ, YuS, NishSA, LauferTM, MedzhitovR: Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response.Nat. Immunol.10(7) , 713–720 (2009).
  • Ito T , WangYH, DuramadO et al.: TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.J. Exp. Med.202(9) , 1213–1223 (2005).
  • Manel N , UnutmazD, LittmanDR: The differentiation of human Th-17 cells requires transforming growth factor-β and induction of the nuclear receptor ROR-γ-t.Nat. Immunol.9(6) , 641–649 (2008).
  • Jego G , PascualV, PaluckaAK, BanchereauJ: Dendritic cells control B-cell growth and differentiation.Curr. Dir. Autoimmun.8 , 124–139 (2005).
  • Munz C , DaoT, FerlazzoG, De Cos MA, Goodman K, Young JW: Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood105(1) , 266–273 (2005).
  • Fujii S , ShimizuK, KronenbergM, SteinmanRM: Prolonged IFN-γ-producing nkt response induced with α-galactosylceramide-loaded DCs.Nat. Immunol.3(9) , 867–874 (2002).
  • Cools N , PonsaertsP, Van Tendeloo VF, Berneman ZN: Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J. Leukoc. Biol.82(6) , 1365–1374 (2007).
  • Mellor AL , MunnDH: IDO expression by dendritic cells: tolerance and tryptophan catabolism.Nat. Rev. Immunol.4(10) , 762–774 (2004).
  • Munn DH , MellorAL: IDO and tolerance to tumors.Trends Mol. Med.10(1) , 15–18 (2004).
  • Levings MK , GregoriS, TresoldiE, CazzanigaS, BoniniC, RoncaroloMG: Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells.Blood105(3) , 1162–1169 (2005).
  • Jonuleit H , SchmittE, SchulerG, KnopJ, EnkAH: Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.J. Exp. Med.192(9) , 1213–1222 (2000).
  • Woo EY , ChuCS, GoletzTJ et al.: Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.Cancer Res.61(12) , 4766–4772 (2001).
  • Liyanage UK , MooreTT, JooHG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.J. Immunol.169(5) , 2756–2761 (2002).
  • Viehl CT , MooreTT, LiyanageUK et al.: Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.Ann. Surg. Oncol.13(9) , 1252–1258 (2006).
  • Chen W , LiangX, PetersonAJ, MunnDH, BlazarBR: The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive t regulatory cell generation.J. Immunol.181(8) , 5396–5404 (2008).
  • Skoberne M , SomersanS, AlmodovarW et al.: The apoptotic-cell receptor CR3, but not αVβ5, is a regulator of human dendritic-cell immunostimulatory function.Blood108(3) , 947–955 (2006).
  • Skoberne M , BeignonAS, LarssonM, BhardwajN: Apoptotic cells at the crossroads of tolerance and immunity.Curr. Top. Microbiol. Immunol.289 , 259–292 (2005).
  • Satzger I , SchenckF, KappA, GutzmerR: Spontaneous regression of melanoma with distant metastases – report of a patient with brain metastases.Eur. J. Dermatol.16(4) , 454–455 (2006).
  • Wang RF , RosenbergSA: Human tumor antigens for cancer vaccine development.Immunol. Rev.170 , 85–100 (1999).
  • Kim R , EmiM, TanabeK: Cancer immunoediting from immune surveillance to immune escape.Immunology121(1) , 1–14 (2007).
  • Smyth MJ , DunnGP, SchreiberRD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.Adv. Immunol.90 , 1–50 (2006).
  • Gandhi RT , O‘neillD, BoschRJ et al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. Canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.Vaccine27(43) , 6088–6094 (2009).
  • Palucka AK , UenoH, ConnollyJ et al.: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.J. Immunother.29(5) , 545–557 (2006).
  • Redman BG , ChangAE, WhitfieldJ et al.: Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.J. Immunother.31(6) , 591–598 (2008).
  • O‘neill DW , BhardwajN: Differentiation of peripheral blood monocytes into dendritic cells.Curr. Protoc. Immunol. Chapter 22, Unit 22F 4 (2005).
  • O‘neill D , BhardwajN: Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy.Methods Mol. Med.109 , 97–112 (2005).
  • Obermaier B , DauerM, HertenJ, SchadK, EndresS, EiglerA: Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes.Biol. Proced. Online5 , 197–203 (2003).
  • Dauer M , ObermaierB, HertenJ et al.: Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.J. Immunol.170(8) , 4069–4076 (2003).
  • Alldawi L , TakahashiM, NaritaM et al.: Effect of prostaglandin E2, lipopolysaccharide, IFN-γ and cytokines on the generation and function of fast-DC.Cytotherapy7(2) , 195–202 (2005).
  • Jarnjak-Jankovic S , HammerstadH, Saeboe-LarssenS, KvalheimG, GaudernackG: A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines.BMC Cancer7 , 119 (2007).
  • Banchereau J , PaluckaAK, DhodapkarM et al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine.Cancer Res.61(17) , 6451–6458 (2001).
  • Klechevsky E , LiuM, MoritaR et al.: Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines.Hum. Immunol.70(5) , 281–288 (2009).
  • Fay JW , PaluckaAK, PaczesnyS et al.: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells.Cancer Immunol. Immunotherapy55 , 1209–1218 (2006).
  • Banchereau J , UenoH, DhodapkarM et al.: Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.J. Immunother.28 , 505–516 (2005).
  • Marroquin CE , WestwoodJA, LapointeR et al.: Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.J. Immunother.25(3) , 278–288 (2002).
  • Pulendran B , BanchereauJ, BurkeholderS et al.: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo.J. Immunol.165(1) , 566–572 (2000).
  • Small EJ , SchellhammerPF, HiganoCS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.J. Clin. Oncol.24(19) , 3089–3094 (2006).
  • Dhodapkar MV , SteinmanRM, KrasovskyJ, MunzC, BhardwajN: Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells.J. Exp. Med.193(2) , 233–238 (2001).
  • Dhodapkar MV , SteinmanRM: Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans.Blood100(1) , 174–177 (2002).
  • De Vries IJ , LesterhuisWJ, ScharenborgNM et al.: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.Clin. Cancer Res.9(14) , 5091–5100 (2003).
  • De Vries IJ , KrooshoopDJ, ScharenborgNM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.Cancer Res.63(1) , 12–17 (2003).
  • Lee AW , TruongT, BickhamK et al.: A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.Vaccine20(Suppl. 4) , A8–A22 (2002).
  • Jongmans W , TiemessenDM, Van Vlodrop IJ, Mulders PF, Oosterwijk E: Th1-polarizing capacity of clinical-grade dendritic cells is triggered by ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J. Immunother.28(5) , 480–487 (2005).
  • Krause P , SingerE, DarleyPI, KlebensbergerJ, GroettrupM, LeglerDF: Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T-cell stimulatory capacity despite IDO.J. Leukoc. Biol.82(5) , 1106–1114 (2007).
  • Morelli AE , ThomsonAW: Dendritic cells under the spell of prostaglandins.Trends Immunol.24(3) , 108–111 (2003).
  • Scandella E , MenY, GillessenS, ForsterR, GroettrupM: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells.Blood100(4) , 1354–1361 (2002).
  • Krause P , BrucknerM, UermosiC, SingerE, GroettrupM, LeglerDF: Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4–1-βBL on dendritic cells.Blood113(11) , 2451–2460 (2009).
  • Mailliard RB , Wankowicz-KalinskaA, CaiQ et al.: α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.Cancer Res.64(17) , 5934–5937 (2004).
  • Lee JJ , FoonKA, MailliardRB, MuthuswamyR, KalinskiP: Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.J. Leukoc. Biol.84(1) , 319–325 (2008).
  • Schnare M , BartonGM, HoltAC, TakedaK, AkiraS, MedzhitovR: Toll-like receptorscontrol activation of adaptive immune responses.Nat. Immunol.2(10) , 947–950 (2001).
  • Napolitani G , RinaldiA, BertoniF, SallustoF, LanzavecchiaA: Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.Nat. Immunol.6(8) , 769–776 (2005).
  • Boullart AC , AarntzenEH, VerdijkP et al.: Maturation of monocyte-derived dendritic cells with toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.Cancer Immunol. Immunother.57(11) , 1589–1597 (2008).
  • Speetjens FM , KuppenPJ, WeltersMJ et al.: Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.Clin Cancer Res15(3) , 1086–1095 (2009).
  • Melief CJ , Van Der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer8(5) , 351–360 (2008).
  • Barrou B , BenoitG, OuldkaciM et al.: Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.Cancer Immunol. Immunother.53(5) , 453–460 (2004).
  • Salcedo M , BercoviciN, TaylorR et al.: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.Cancer Immunol. Immunother.55(7) , 819–829 (2006).
  • Mahdian R , KokhaeiP, NajarHM, DerkowK, ChoudhuryA, MellstedtH: Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific anti-tumor T cells.Med. Oncol.23(2) , 273–282 (2006).
  • Schnurr M , GalambosP, ScholzC et al.: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.Cancer Res.61(17) , 6445–6450 (2001).
  • Thumann P , MocI, HumrichJ et al.: Antigen loading of dendritic cells with whole tumor cell preparations.J. Immunol. Methods277(1–2) , 1–16 (2003).
  • Schnurr M , ChenQ, ShinA et al.: Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.Blood105(6) , 2465–2472 (2005).
  • Jenne L , SchulerG, SteinkassererA: Viral vectors for dendritic cell-based immunotherapy.Trends Immunol.22(2) , 102–107 (2001).
  • Brockstedt DG , DubenskyTW: Promises and challenges for the development of listeria monocytogenes-based immunotherapies.Expert Rev. Vaccines7(7) , 1069–1084 (2008).
  • Bellone S , El-SahwiK, CoccoE et al.: Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.J. Virol.83(13) , 6779–6789 (2009).
  • Carrasco J , Van Pel A, Neyns B et al.: Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol.180(5) , 3585–3593 (2008).
  • Butterfield LH , Comin-AnduixB, VujanovicL et al.: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.J. Immunother.31(3) , 294–309 (2008).
  • Veron P , AlloV, RiviereC, BernardJ, DouarAM, MasurierC: Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2.J. Virol.81(10) , 5385–5394 (2007).
  • Skoberne M , YewdallA, BahjatKS et al.: KBMA listeria monocytogenesis an effective vector for DC-mediated induction of anti-tumor immunity.J. Clin. Invest.118(12) , 3990–4001 (2008).
  • Breckpot K , AertsJL, ThielemansK: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.Gene Ther.14(11) , 847–862 (2007).
  • He Y , MunnD, FaloLD Jr: Recombinant lentivector as a genetic immunization vehicle for anti-tumor immunity. Expert Rev. Vaccines6(6) , 913–924 (2007).
  • Schroers R , SinhaI, SegallH et al.: Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.Mol. Ther.1(2) , 171–179 (2000).
  • Dyall J , LatoucheJB, SchnellS, SadelainM: Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes.Blood97(1) , 114–121 (2001).
  • Lizee G , GonzalesMI, TopalianSL: Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.Hum. Gene Ther.15(4) , 393–404 (2004).
  • He Y , ZhangJ, MiZ, RobbinsP, FaloLD Jr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T-cell responses and therapeutic immunity. J. Immunol.174(6) , 3808–3817 (2005).
  • Dullaers M , Van Meirvenne S, Heirman C et al.: Induction of effective therapeutic anti-tumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther.13(7) , 630–640 (2006).
  • Breckpot K , HeirmanC, De Greef C, Van Der Bruggen P, Thielemans K: Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol.172(4) , 2232–2237 (2004).
  • Yang L , YangH, RideoutK et al.: Engineered lentivector targeting of dendritic cells for in vivo immunization.Nat. Biotechnol.26(3) , 326–334 (2008).
  • Nair SK , MorseM, BoczkowskiD et al.: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.Ann. Surg.235(4) , 540–549 (2002).
  • Muller MR , TsakouG, GrunebachF, SchmidtSM, BrossartP: Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.Blood103(5) , 1763–1769 (2004).
  • Nencioni A , MullerMR, GrunebachF et al.: Dendritic cells transfected with tumor RNA for the induction of anti-tumor CTL in colorectal cancer.Cancer Gene Ther.10(3) , 209–214 (2003).
  • Milazzo C , ReichardtVL, MullerMR, GrunebachF, BrossartP: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA.Blood101(3) , 977–982 (2003).
  • Gilboa E , ViewegJ: Cancer immunotherapy with mRNA-transfected dendritic cells.Immunol. Rev.199 , 251–263 (2004).
  • Heiser A , MauriceMA, YanceyDR, ColemanDM, DahmP, ViewegJ: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.Cancer Res.61(8) , 3388–3393 (2001).
  • Strobel I , BerchtoldS, GotzeA, SchulzeU, SchulerG, SteinkassererA: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes.Gene Ther.7(23) , 2028–2035 (2000).
  • Koido S , KashiwabaM, ChenD, GendlerS, KufeD, GongJ: Induction of anti-tumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.J. Immunol.165(10) , 5713–5719 (2000).
  • Heiser A , ColemanD, DannullJ et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J. Clin. Invest.109(3) , 409–417 (2002).
  • Shortman K , LahoudMH, CaminschiI: Improving vaccines by targeting antigens to dendritic cells.Exp. Mol. Med.41(2) , 61–66 (2009).
  • Tacken PJ , TorensmaR, FigdorCG: Targeting antigens to dendritic cellsin vivo.Immunobiology211(6–8) , 599–608 (2006).
  • Jinushi M , HodiFS, DranoffG: Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.Immunol. Rev.222 , 287–298 (2008).
  • Jinushi M , TaharaH: Cytokine gene-mediated immunotherapy: current status and future perspectives.Cancer Sci.100(8) , 1389–1396 (2009).
  • Luiten RM , KueterEW, MooiW et al.: Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.J. Clin. Oncol.23 , 8978–8991 (2005).
  • Small EJ , NemunaitisJ, MarshallF et al.: Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.Clin. Cancer Res.13 , 1883–3891 (2007).
  • Higano CS : Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.Cancer113 , 975–984 (2008).
  • Filipazzi P , ValentiR, HuberV et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based anti-tumor vaccine.J. Clin. Oncol.25(18) , 2546–2553 (2007).
  • Sica A , BronteV: Altered macrophage differentiation and immune dysfunction in tumor development.J. Clin. Invest.117(5) , 1155–1166 (2007).
  • Van Kooyk Y : C-type lectins on dendritic cells: key modulators for the induction of immune responses.Biochem. Soc. Trans.36(Pt 6) , 1478–1481 (2008).
  • Caminschi I , ProiettoAI, AhmetF et al.: The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.Blood112(8) , 3264–3273 (2008).
  • Carter RW , ThompsonC, ReidDM, WongSY, ToughDF: Preferential induction of CD4+ T-cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1.J. Immunol.177(4) , 2276–2284 (2006).
  • Carter RW , ThompsonC, ReidDM, WongSY, ToughDF: Induction of CD8+ T-cell responses through targeting of antigen to dectin-2.Cell. Immunol.239(2) , 87–91 (2006).
  • Boscardin SB , HafallaJC, MasilamaniRF et al.: Antigen targeting to dendritic cells elicits long-lived T-cell help for antibody responses.J. Exp. Med.203(3) , 599–606 (2006).
  • Ramakrishna V , TremlJF, VitaleL et al.: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T-cell responses via multiple HLA molecules.J. Immunol.172(5) , 2845–2852 (2004).
  • Adema GJ , De Vries IJ, Punt CJ, Figdor CG: Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol.17(2) , 170–174 (2005).
  • Verdijk P , AarntzenEH, LesterhuisWJ et al.: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.Clin. Cancer Res.15(7) , 2531–2540 (2009).
  • Schadendorf D , UgurelS, Schuler-ThurnerB et al.: Dacarbazine (Dtic) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the decog.Ann. Oncol.17(4) , 563–570 (2006).
  • Higano CS , SchellhammerPF, SmallEJ et al.: Integrated data from 2 randomized, double-blind, placebo-controlled, Phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.Cancer115(16) , 3670–3679 (2009).
  • Finn OJ , ForniG: Prophylactic cancer vaccines.Curr. Opin. Immunol.14(2) , 172–177 (2002).
  • Jocham D , RichterA, HoffmannL et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial.Lancet363(9409) , 594–599 (2004).
  • Bronte V , MocellinS: Suppressive influences in the immune response to cancer.J. Immunother.32(1) , 1–11 (2009).
  • Bennaceur K , ChapmanJ, Brikci-NigassaL, SanhadjiK, TouraineJL, PortoukalianJ: Dendritic cells dysfunction in tumour environment.Cancer Lett.272(2) , 186–196 (2008).
  • Aptsiauri N , CabreraT, MendezR, Garcia-LoraA, Ruiz-CabelloF, GarridoF: Role of altered expression of HLA class I molecules in cancer progression.Adv. Exp. Med. Biol.601 , 123–131 (2007).
  • Chang CC , OginoT, MullinsDW et al.: Defective human leukocyte antigen class I-associated antigen presentation caused by a novel b2-microglobulin loss-of-function in melanoma cells.J. Biol. Chem.281(27) , 18763–18773 (2006).
  • Blank C , GajewskiTF, MackensenA: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.Cancer Immunol Immunother54(4) , 307–314 (2005).
  • Iwai Y , IshidaM, TanakaY, OkazakiT, HonjoT, MinatoN: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc. Natl Acad. Sci. USA99(19) , 12293–12297 (2002).
  • Strome SE , DongH, TamuraH et al.: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.Cancer Res.63(19) , 6501–6505 (2003).
  • Blank C , KuballJ, VoelklS et al.: Blockade of PD-L1 (B7-H1) augments human tumor-specific T-cell responses in vitro.Int. J. Cancer119(2) , 317–327 (2006).
  • Berger R , Rotem-YehudarR, SlamaG et al.: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.Clin. Cancer Res.14(10) , 3044–3051 (2008).
  • Peggs KS , QuezadaSA, ChambersCA, KormanAJ, AllisonJP: Blockade of CTLA-4 on both effector and regulatory T-cell compartments contributes to the anti-tumor activity of anti-CTLA-4 antibodies.J. Exp. Med. (2009).
  • Yuan J , GnjaticS, LiH et al.: CTLA-4blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit.Proc. Natl Acad. Sci. USA105(51) , 20410–20415 (2008).
  • O‘day SJ , HamidO, UrbaWJ: Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.Cancer110(12) , 2614–2627 (2007).
  • Gilboa E : Knocking the SOCS1 off dendritic cells.Nat. Biotechnol.22(12) , 1521–1522 (2004).
  • Croker BA , KiuH, NicholsonSE: SOCS regulation of the JAK/STAT signalling pathway.Semin. Cell Dev. Biol.19(4) , 414–422 (2008).
  • Shen L , Evel-KablerK, StrubeR, ChenSY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.Nat. Biotechnol.22(12) , 1546–1553 (2004).
  • Evel-Kabler K , SongXT, AldrichM, HuangXF, ChenSY: SOCS1 restricts dendritic cells‘ ability to break self tolerance and induce anti-tumor immunity by regulating IL-12 production and signaling.J. Clin. Invest.116(1) , 90–100 (2006).
  • Cohen N , MoulyE, HamdiH et al.: Gilz expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response.Blood107(5) , 2037–2044 (2006).
  • Berrebi D , BruscoliS, CohenN et al.: Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10.Blood101(2) , 729–738 (2003).
  • Foss F : Clinical experience with denileukin diftitox (ONTAK).Semin. Oncol.33(1 Suppl. 3) , S11–S16 (2006).
  • Liu JY , WuY, ZhangXS et al.: Single administration of low dose cyclophosphamide augments the anti-tumor effect of dendritic cell vaccine.Cancer Immunol. Immunother.56(10) , 1597–1604 (2007).
  • Shimizu J , YamazakiS, TakahashiT, IshidaY, SakaguchiS: Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance.Nat. Immunol.3(2) , 135–142 (2002).
  • Ko K , YamazakiS, NakamuraK et al.: Treatment of advanced tumors with agonistic anti-gitr mab and its effects on tumor-infiltrating 3+CD25+CD4+ regulatory T cells.J. Exp. Med.202(7) , 885–891 (2005).
  • Cohen AD , DiabA, PeralesMA et al.: Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity.Cancer Res.66(9) , 4904–4912 (2006).
  • Vicari AP , ChiodoniC, VaureC et al.: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.J. Exp. Med.196(4) , 541–549 (2002).
  • Fujita T , TeramotoK, OzakiY et al.: Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments anti-tumor responses by various immunologic cell types.Cancer Res.69(12) , 5142–5150 (2009).
  • Lopez MN , PeredaC, SegalG et al.: Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells.J. Clin. Oncol.27(6) , 945–952 (2009).
  • Wang C , LinGH, McphersonAJ, WattsTH: Immune regulation by 4-1-βB and 4-1-βBL: complexities and challenges.Immunol. Rev.229(1) , 192–215 (2009).
  • May KF Jr, Chen L, Zheng P, Liu Y: Anti-4-1-βB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res.62(12) , 3459–3465 (2002).
  • Murillo O , DubrotJ, PalazonA et al.: in vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.Eur. J. Immunol.39(9) , 2424–2436 (2009).
  • Kocak E , LuteK, ChangX et al.: Combination therapy with anti-CTL antigen-4 and anti-4-1-βB antibodies enhances cancer immunity and reduces autoimmunity.Cancer Res.66(14) , 7276–7284 (2006).
  • Hanks BA , JiangJ, SinghRA et al.: Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.Nat. Med.11(2) , 130–137 (2005).
  • Lapteva N , SeethammagariMR, HanksBA et al.: Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation.Cancer Res.67(21) , 10528–10537 (2007).
  • Kutzler MA , RobinsonTM, ChattergoonMA et al.: Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T-cell help.J. Immunol.175(1) , 112–123 (2005).
  • Klebanoff CA , FinkelsteinSE, SurmanDR et al.: IL-15 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells.Proc. Natl Acad. Sci. USA101(7) , 1969–1974 (2004).
  • Teague RM , SatherBD, SacksJA et al.: Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.Nat. Med.12(3) , 335–341 (2006).
  • Schluns KS , KieperWC, JamesonSC, LefrancoisL: Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo.Nat. Immunol.1(5) , 426–432 (2000).
  • Rosenberg SA , SportesC, AhmadzadehM et al.: IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.J. Immunother.29(3) , 313–319 (2006).
  • Minkis K , KavanaghDG, AlterG et al.: Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.Cancer Res.68(22) , 9441–9450 (2008).
  • Czerniecki BJ , KoskiGK, KoldovskyU et al.: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.Cancer Res.67(4) , 1842–1852 (2007).
  • Adams S , O‘neillDW, NonakaD et al.: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.J. Immunol.181(1) , 776–784 (2008).
  • Speiser DE , LienardD, RuferN et al.: Rapid and strong human CD8+ T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.J. Clin. Invest.115(3) , 739–746 (2005).
  • Warger T , OsterlohP, Rechtsteiner Get al.: Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood108(2) , 544–550 (2006).
  • Vandepapeliere P , HorsmansY, MorisP et al.: Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T-cell responses against hepatitis B surface antigen in healthy adult volunteers.Vaccine26(10) , 1375–1386 (2008).
  • Longhi MP , TrumpfhellerC, IdoyagaJ et al.: Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.J. Exp. Med.206(7) , 1589–1602 (2009).
  • Reed SG , BertholetS, ColerRN, FriedeM: New horizons in adjuvants for vaccine development.Trends Immunol.30(1) , 23–32 (2009).
  • Sharp FA , RuaneD, ClaassB et al.: Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.Proc. Natl Acad. Sci. USA106(3) , 870–875 (2009).
  • Baumgaertner P , RuferN, DevevreE et al.: ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.Cancer Res.66(4) , 1912–1916 (2006).
  • Diefenbach CS , GnjaticS, SabbatiniP et al.: Safety and immunogenicity study of NY-ESO-1-β peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.Clin. Cancer Res.14(9) , 2740–2748 (2008).
  • Fourcade J , KudelaP, Andrade Filho PAet al.: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother.31(8) , 781–791 (2008).
  • Marshall JL , GulleyJL, ArlenPM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.J. Clin. Oncol.23(4) , 720–731 (2005).
  • Marshall JL , HoyerRJ, ToomeyMA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.J. Clin. Oncol.18(23) , 3964–3973 (2000).
  • Dhodapkar MV : Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.Front. Biosci.14 , 796–807 (2009).
  • Chang DH , OsmanK, ConnollyJ et al.: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients.J. Exp. Med.201(9) , 1503–1517 (2005).
  • Aquino A , FormicaV, PreteSP et al.: Drug-induced increase of carcinoembryonic antigen expression in cancer cells.Pharmacol. Res.49(5) , 383–396 (2004).
  • Correale P , AquinoA, GiulianiA et al.: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.Int. J. Cancer104(4) , 437–445 (2003).
  • Lu W , ArraesLC, FerreiraWT, AndrieuJM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.Nat. Med.10(12) , 1359–1365 (2004).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.